Promising Results from Prostate Device Study
Published date : 03 October 2012
Article date : 03 October 2012
Masshightech.com reports on a study about a device designed for use in the treatment of prostate cancer which states that it can discriminate between cancer and healthy tissue with “a very high degree of accuracy.”
Apparently, the MarginProbe System is Dune Medical Devices's first commercial product and it is now approved and available in Europe for use in detecting diseased tissue in breast cancer patients. A prototype of the device for prostate cancer is based on the same technology but shaped differently than the breast cancer device. It is now in feasibility studies.
The study published in Nature.com involved more than 15,000 measurements in 49 patients. The abstract from the study reported the device's ability to discriminate between malignant and nonmalignant cells with a sensitivity and specificity of between 68.4% and 93.6% depending on the size of the cancer. The abstract of the Nature.com article concludes, "First results from a radio-frequency near-field spectroscopy sensor look promising for differentiation between cancer and benign prostate tissue."
Source: By Don Seiffert, masshightech.com, 17 September 2012
Read the original article here.
